ArchPoint Investors’s Eli Lilly LLY Stock Holding History

ArchPoint Investors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,293	Closed	-$530K	–	94
2021 Q3	$530K	Buy	+2,293	New	+$566K	0.16%	55

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ArchPoint Investors's LLY Position: Q4 2021 in Review

ArchPoint Investors sold out of Eli Lilly (LLY) in Q4 2021, closing a stake of 2,293 shares — an estimated $530K sold.

ArchPoint Investors first reported a position in LLY in Q3 2021 and held it in 1 quarter. The position peaked at $530K in Q3 2021. 2,304 funds tracked by Wall St. Rank hold LLY as of Q4 2021.

ArchPoint Investors reported no remaining Eli Lilly position as of Q4 2021 after selling out during the quarter.
ArchPoint Investors sold 2,293 Eli Lilly shares in Q4 2021, an estimated $530K.
ArchPoint Investors first reported a position in Eli Lilly in Q3 2021 and held it in 1 quarter.
ArchPoint Investors's Eli Lilly position peaked at $530K in Q3 2021.
2,304 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2021.

Based on ArchPoint Investors's 13F filing for Q4 2021, filed 11 Feb 2022.